ArticleNPJ vaccines2018
A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice.
Article in NPJ vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 55 citations in OpenAlex.
- Oropouche virus causes severe congenital disease in embryonic mice.Nature communications · 2026Article
- Article
- Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates.Nature communications · 2025Article
- Three-dimensional mapping of tick-borne encephalitis virus distribution in the mouse brain using a newly engineered TurboGFP reporter virus.Emerging microbes & infections · 2025Article
- Manipulating Zika virus RNA tertiary structure for developing tissue-specific attenuated vaccines.EMBO molecular medicine · 2025Article
- Review
- Immunofluorescence Assay.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Epidemic Zika virus strains from the Asian lineage induce an attenuated fetal brain pathogenicity.Nature communications · 2024Article
- Immunogenicity and Protective Efficacy of Aerosolized Live-Attenuated Yellow Fever 17D Vaccine in Mice.Vaccines · 2024Article
- Parallel Multifactorial Process Optimization and Intensification for High-Yield Production of Live YF17D-Vectored Zika Vaccine.Vaccines · 2024Article
- Zika Virus-A Reemerging Neurotropic Arbovirus Associated with Adverse Pregnancy Outcomes and Neuropathogenesis.Pathogens (Basel, Switzerland) · 2024Review
- Multiplexed multicolor antiviral assay amenable for high-throughput research.Nature communications · 2024Article
- YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge.NPJ vaccines · 2023Article
- Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models.NPJ vaccines · 2023Article
- Development and characterization of chimera of yellow fever virus vaccine strain and Tick-Borne encephalitis virus.PloS one · 2023Article
- Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.EBioMedicine · 2022Article
- A High-Throughput Yellow Fever Neutralization Assay.Microbiology spectrum · 2022Article
- Investigation of immune response induction by Japanese encephalitis live-attenuated and chimeric vaccines in mice.MedComm · 2022Article
- Article
- Single dose of chimeric dengue-2/Zika vaccine candidate protects mice and non-human primates against Zika virus.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent Zika virus (ZIKV) epidemic in the Americas led to an intense search for therapeutics and vaccines. Here we report the engineering of a chimeric virus vaccine candidate (YF-ZIKprM/E) by replacing the antigenic surface glycoproteins and the capsid anchor of YFV-17D with those of a prototypic Asian lineage ZIKV isolate. By intracellular passaging, a variant with adaptive mutations in the E protein was obtained. Unlike YFV-17D, YF-ZIKprM/E replicates poorly in mosquito cells. Also, YF-ZIKprM/E does not cause disease nor mortality in interferon α/β, and γ receptor KO AG129 mice nor following intracranial inoculation of BALB/c pups. A single dose as low as 1 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.